MalignantSoft tissue
Leiomyosarcoma
Synonyms: LMS, Smooth muscle sarcoma
Second most common STS
Quick Facts
Behaviour
Malignant
Category
Soft tissue
Grade
Variable
Synonyms
- LMS
- Smooth muscle sarcoma
Category
Soft tissue
Behaviour
Malignant
Grade
Variable
Gender
M = F
Tissue of Origin
Smooth muscle
Epidemiology
- Second most common STS in adults
- Peak incidence 50-70 years
- Can arise in any location with smooth muscle
- Often deep-seated and large at diagnosis
Clinical Features
- Painless or mildly painful mass
- Rapid growth in some cases
- May present with complications (GI bleeding if visceral)
Location
- Retroperitoneum
- Deep tHigh
- GI tract
- Biliary tract
- Subcutaneous tissues (rare)
Imaging
- MRI shows heterogeneous T2 signal
- Varying enhancement post-contrast
- May show necrosis or hemorrhage
- Difficult to distinguish from Benign leiomyoma
Pathology
- Fascicular arrangement of smooth muscle cells
- Increased mitotic activity
- Spindle cell morphology
- Cytologic atypia
Genetics
- No specific recurrent cytogenetic abnormality
- Complex karyotypes common
Treatment
- Wide surgical excision primary treatment
- Adjuvant chemotherapy for High-grade/large tumours
- Radiotherapy for unresectable or recurrent disease
Prognosis
- Grade and size most important prognostic factors
- 5-year survival 50% for High-grade
- Retroperitoneal location associated with worse prognosis
Key Points
- Second most common STS
- Often presents at advanced stage
- Grade and depth crucial for treatment planning
- Regular imaging Follow-up essential
Workup - Local Imaging
MRI with contrast
Workup - Biopsy
- Core needle biopsy recommended
- Assess grade and mitotic activity
Workup - Staging
CT CAP
Follow-up Summary
- Years 1–2: 3–4 monthly clinical review + CXR; MRI primary site at 3 months post-op then 6-monthly
- CT chest every 3–4 months for first 2 years (pulmonary metastasis is primary concern)
- Years 3–5: 6-monthly clinical review + CXR; CT chest 6-monthly
- Years 6–10: Annual clinical review + CXR; CT chest annually
- Discharge at 10 years with documented self-monitoring advice
- Radiotherapy patients: monitor irradiated field for late effects at each review